Generative AI is revolutionizing Drug-Target Interaction (DTI) prediction by automating drug design, improving binding accuracy, and accelerating discovery timelines. It replaces manual, trial-and-error methods with predictive, end-to-end pipelines. While challenges like interpretability and data quality persist, real-world case studies show its promise. GenAI is set to reshape pharma by making drug discovery faster, smarter, and more scalable.

This blog explores how Gen AI is transforming R&D workflows by improving ADMET predictions, reducing risk, and enhancing decision-making. It highlights Kwapio, an AI-powered platform developed by Pitchworks Gen AI Labs and GCC, which integrates predictive models with project management. The result: faster, more accurate drug development and better collaboration across biotech, CROs, and pharma teams.